Compass Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
CMPX$0.84+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
(In thousands)
| For the Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(34,342) | $(29,079) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 449 | 538 |
| Share-based compensation | 6,322 | 4,520 |
| Amortization of premium and discount on marketable securities | (1,381) | (2,414) |
| ROU asset amortization | 945 | 884 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (4,318) | 5,301 |
| Accounts payable | (3,130) | (1,076) |
| Accrued expenses | 402 | (6,046) |
| Operating lease liability | (640) | (892) |
| Net cash used in operating activities | (35,693) | (28,264) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (78,297) | (110,339) |
| Proceeds from sale or maturities of marketable securities | 109,743 | 131,011 |
| Purchases of property and equipment | (44) | (21) |
| Net cash provided by investing activities | 31,402 | 20,651 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock | 18,113 | 3,126 |
| Issuance costs from issuance of common stock | (545) | (95) |
| Taxes paid related to net shares settlement of RSUs | (136) | — |
| Proceeds from exercise of stock options | — | 62 |
| Net cash provided by financing activities | 17,432 | 3,093 |
| Net change in cash, cash equivalents and restricted cash | 13,141 | (4,520) |
| Cash, cash equivalents and restricted cash at beginning of period | 24,228 | 34,946 |
| Cash, cash equivalents and restricted cash at end of period | $37,369 | $30,426 |
| Supplemental disclosure of cash flow information | ||
| Unrealized loss (gain) on marketable securities | $(449) | $128 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.